We can say goodbye to any potential formulary wins in 2019. Leadership should have done the same thing last year...layoffs 2018 just got more interesting.
Amgen has had 7 months to lower cost after March ACC meeting . What happens when Outcomes gets published and label changes and indications change ?? How will Repatha do then???
Yea , I just say what took so long Amgen? With our outcomes data and reduction in Mortality with Praluent I guess they needed to do something.. Fourier is sunk
Hahahahaha. Praluent is dead money. Just like Sanofi. Insurance companies and doctors don’t see a difference in the two products. They are commodities. The one with the cheapest price wins. You guys lose. Time to shelve this dog. More cuts coming, but you already knew that.
You guys? Ok Amgen troll !! Your throwing everything but the kitchen sink into your product (TV ads, Time magazine and other magazines, your so called outcomes Fourier data, ratio of 9 to 2 reps per territory) and you still suck in sales!! Hahahahaha
Yeah we suck money. When u steal patent and the penalties enforced will only cripple the product bye bye sanofi.
It will be lowering of both products prices and since they are commodities, they will not need reps on both sides.
Well ain’t that something... http://annals.org/aim/article-abstract/2719987/cost-effectiveness-alirocumab-just-time-analysis-based-odyssey-outcomes-trial And the hits keep coming.
